JonesTrading assumes coverage of Prime Medicine with buy rating; target price $6
PRME•JonesTrading assumed coverage of Prime Medicine with a buy rating and a $6 target price.
Related News
Malibu Boats Q1 net income USD -6.1 million
MBUU•
Aclaris Therapeutics Q3 net loss widens 27% to $18.51 million
ACRS•
Lightspeed Q2 net loss narrows 87% to USD 4.23 million; revenue rises to USD 323.79 million
LSPD•
Unity Software Q3 revenue $622 million vs. IBES estimate $567.4 million
U•
ConocoPhillips beats quarterly profit estimates
COP•